|
|
215 Redfern Avenue Suite 100
Montreal, Quebec H3Z 3L5 Canada
phone:(1) 514 282 3350
fax:(1) 514 282 3358
|
|
| Symbol |
HAE |
| Exchange |
TSX |
| Founded |
1991 |
| Employees |
|
|
|
| www.haemacure.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Surgical devices, adhesives, and biomaterials for surgical wound care |
|
| Management |
| Joseph Galli, Chairman of the Board and Chief Executive Officer; Marc Paquin, President and Director; Christian Hours, Ph.D., Vice President, Quality and Technical Affairs; Lyne Par, CA, Director, Finance and Administration; Gilles Lemieux, B.Com., LL.L., Corporate Secretary, Investor Relations; Dawn Benson, Director of Quality Assurance and Quality Control |
| |
|
|
|
|
|
|
|
| Keywords |
| wound, woundcare, Surgery Products, Surgery, hemostat, plasma proteins |
|
|
|
| Description |
|
Haemacure Corporation is a specialty bio-therapeutics company developing high-value human biological adhesives, therapeutic proteins, and hemostats for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology used to develop next-generation products, including surgical hemostats (instruments to prevent flow of blood from an open blood vessel). |
|
| Products / Services |
Haemacure's lead product candidate, Hemaseel(R) HMN, is a human-derived fibrin sealant in late-stage clinical development. Haemacure's second product candidate is a hemostat consisting of human thrombin, a component of its fibrin sealant. Product development activities focus on surgical hemostats-and their combinations with biomaterials-as well as drug delivery in select therapeutic areas.
|
|
| Technology / Differentiation |
| Haemacure's technologies utilize fibrinogen and thrombin from human plasma to arrest bleeding, seal tissues and act as an adjunct to wound healing. The synthesis of Haemacure products from human plasma, and not from bovine components, precludes any cross-species immunological risks and disease transmission. |
|
| Market / Customers |
Haemacure's fibrin sealant and hemostats have numerous applications in the bio-surgical market, which is expected to grow at double-digit rates until 2015 to reach a U.S. market value of $1.5 billion.
|
|
| Status |
| Haemacure projects to have patients undergo surgery with its fibrin sealant as part of a clinical trial early in 2009. It will commercially launch its fibrin sealant in late 2010-early 2011. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
